Macrobid (nitrofurantoin monohydrate/ macrocrystals) Procter & Gamble Pharmaceuticals 10 Revised March 2003 Allergic Lupus-like syndrome associated with pulmonary reaction to nitrofurantoin has been reported. Also, angioedema; maculopapular, erythematous, or eczematous eruptions; anaphylaxis; arthralgia; myalgia; drug fever; and chills have been reported. Hypersensitivity reactions represent the most frequent spontaneously-reported adverse events in worldwide postmarketing experience with nitrofurantoin formulations. Dermatologic Exfoliative dermatitis and erythema multiforme (including Stevens-Johnson syndrome) have been reported rarely. Hematologic Cyanosis secondary to methemoglobinemia has been reported rarely. Miscellaneous As with other antimicrobial agents, superinfections caused by resistant organisms, e. g., Pseudomonas species or Candida species, can occur. In clinical trials of Macrobid, the most frequent laboratory adverse events (1-5%), without regard to drug relationship, were as follows: eosinophilia, increased AST (SGOT), increased ALT (SGPT), decreased hemoglobin, increased serum phosphorus. The following laboratory adverse events also have been reported with the use of nitrofurantoin: glucose-6-phosphate dehydrogenase deficiency anemia (see WARNINGS), agranulocytosis, leukopenia, granulocytopenia, hemolytic anemia, thrombocytopenia, megaloblastic anemia. In most cases, these hematologic abnormalities resolved following cessation of therapy. Aplastic anemia has been reported rarely. | ||||
Email this article
Printer friendly
Bookmark this pageadvertisement
